Clinical Trials on Hereditary Breast/Ovarian Cancer (brca1, brca2) in Russian Federation
Total 14 results
-
Blokhin's Russian Cancer Research CenterUnknownOvarian Neoplasms | Ovarian Cancer | Chemotherapy | BRCA1 Mutation | BRCA2 Mutation | Serous AdenocarcinomaRussian Federation
-
AstraZenecaCompletedHER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 MutationsItaly, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
-
Tatarstan Cancer CenterUnknownHereditary Breast CancerRussian Federation
-
AstraZenecaMerck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.Active, not recruitingBreast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene MutationItaly, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
-
AstraZenecaRUSSCO (Russian Society of Clinical Oncology)CompletedOvarian, Peritoneal, Fallopian Tube Cancer, BRCAm+ in RussiaRussian Federation
-
Tomsk National Research Medical Center of the Russian...CompletedBreast Cancer | Ovarian Cancer | Endometrial CancerRussian Federation
-
PfizerMedivation, Inc.CompletedBreast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene MutationKorea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
-
PfizerActive, not recruitingHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast CancerUnited States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
-
AstraZenecaMerck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.Active, not recruitingAdvanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum ChemotherapyKorea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
-
AstraZenecaEnrolling by invitationBreast Cancer | Ovarian CancerItaly, Spain, United States, Canada, Belgium, Denmark, Korea, Republic of, Czechia, Turkey, China, United Kingdom, Taiwan, Brazil, Israel, France, Hungary, Poland, Portugal, Germany, Russian Federation, Bulgaria, Finland, Slovenia, Sw...
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingGlioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract CancersUnited States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom
-
AstraZenecaDaiichi Sankyo Co., Ltd.RecruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerCanada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands
-
AstraZenecaRecruitingCervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5Canada, Spain, China, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia